An FDA advisory panel narrowly recommended allowing compounding pharmacies to manufacture the peptide epitalon while voting against manufacturing emideltide. The panel’s decisions follow a similar round that recommended allowing pharmacies to make four other peptides, keeping pressure on unapproved-compound availability efforts. The votes move health secretary Robert F. Kennedy Jr. closer to his stated mission of making these products more available, while highlighting how narrowly the compounding path can hinge on advisory panel scrutiny and safety or efficacy assessments. For pharmacies and manufacturers of peptide ingredients, the split recommendation signals that each peptide may face a distinct evidence bar—even when the policy objective is broadly aligned across the compounding category.